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J I. INTROOOCTION 
Humorally mediated hyperacute rejection (HAR) of primarily 
vascularized renal allografts was originally recognized in 
patients who received kidneys from ABO blood group incompatible 
donors (1). Isohemagglutinins to ABO antigens resulted in rapid 
renal allograft rejection with histologic similarity to the 
generalized Shwartzman reaction (2). It is therefore universally 
accepted that incompatibility for these blood group antigens is a 
major barrier to kidney transplantation. 
Terasaki and colleagues later provided evidence that HAR was 
also possible in the presence of ABO red cell group compatibility 
(3), which was demonstrated to be associated with circulating 
preformed antidonor antibodies to specific MHC determinants. 
This state of recipient presensitization or presence of preformed 
antibodies occurs in those patients who have rejected a previous 
transplant (4), in those who have received multiple blood 
transfusions (5), and secondary to pregnancy (6). A positive 
crossmatch to antibodies directed against HLA -A, B, and in some 
cases HLA-DR, constitutes a contraindication to kidney 
transplantation. However, the same events may not be completely 
applicable to the liver, which has been felt to be resistent to 
this kind of antibody-mediated injury, although rejection of the 
human hear t within a few minutes to a few hours has also been 
reported (7). 
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J Humorally mediated HAR due to preformed antibodies is also 
the mechanism of rejection in discordant xenografts, i.e., 
between widely disparate species. The entire process is 
pathophysiologically very similar, if not identical, to that 
observed in ABO blood group major incompatibility or in the 
presence of serum cytotoxic antigraft antibodies. Therefore HAR 
represent a specific and defined, but incompletely understood, 
entity which can be elicited in different transplant situations 
and in different organs. At present, BAR cannot be managed with 
any significant consistency, and presents the greatest threat to 
kidney transplants, and is increasingly becoming an important 
consideration in cardiac and hepatic transplantation. 
The implications for a better understanding of the 
mechanisms involved in and the management of hyperacute allograft 
rejection are great. Patients with wide ranging antibodies who 
have become noncandidates for renal transplantation could be 
he 1 p e d • For a 11 0 r g an s, the po s sib iIi t Y 0 f us in g x e n og r aft s 
could be considered in the future. 
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J II. MBCBANISM OF ANTIBODY-*EDIATED HYPBRACUTE REJECTION 
The hyperacute rejection which occurs when kidney allografts 
are e x p 0 sed t 0 are c i pie n tan t i g r aft ant i b od i e sin the t h r e e 
different situations already mentioned, fundamentally represents 
a devascularization in which small vessels become plugged with 
coagulation products and formed blood elements (8). This 
immunologically precipitated failure of the microcirculatory 
environment may well follow many of the same final common 
pathways of injury and organ function that can be caused by 
ischemia and toxins as well. Failure of the microc irculatory 
en vir oniT.en t from immune and othe r c au ses rnus t be v iewed as the 
product of a complex inflammatory process. 
The acute inflammatory mediators responsible for tissue 
injury are derived either from plasma proteins or from several 
different types of cells, such as polymorphonuclear leukocytes 
(PMNs), platelets, monocytes, macrophages, lymphocytes and 
endothelial cells. The four classical systems responsible for 
inflammation (i.e., the complement, coagulation, fibrinolysis and 
the kallikrein-kinin systems) generate the inflammatory plasma 
proteins responsible for some of the key pathophysiologic 
processes seen in HAR. These four protein systems interact with 
one another during the activation process, and furthermore, 
interact with and activate the cellular elements already alluded 
to. In fact, it has been the insight recently gained into the 
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cell derived mediators which has allowed a fuller explanation and 
understanding of the interrelationships of the various 
pathophysiologic processes which are further outlined below. 
Preformed mediators such as chemotactic factors, 
lymphokines, histamines, serotonin, oxygen-derived free radicals, 
arachidonic acid metabolites, and acetylated alkyl 
phosphoglycerides (PAF) are released from cells after cell 
stimulation or injury. Such cell-derived mediators have been 
implicated in the modulation of many aspects of the acute 
inflammatory process, and specifically in HAR. Furthermore, the 
vascular endothelium is now considered an important component of 
the inflammatory response. The endothelial cell can release 
various inflarr,matory mediators including prostaglandins (9), 
hydroxy fatty acids (10), and PM (11). Endothelial cells can 
present Ia antigens to circulating lymphocytes and antibodies 
(12), and it can release chemotactic factors for neutrophils 
(13). The endothelial cells that participate in most 
inflammatory responses are found in the microvasculature (14). 
The or ig in al d esc r ipt ion of BAR recogn i zed tha t platelets 
and neutrophils contributed to the process. It is well known 
that various blood elements, specifically platelets and 
neutrophils, interact with the vascular endothelium during the 
process of thrombin formation and vascular occlusion (14) in a 
variety of pathophysiologic processes including antibody mediated 
organ rejection and organ ischemia. Interactions among these 
cells can lead to the formation and release of vasoactive 
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J substances that have the potential to modulate regional blood 
flow (15), and the importance of localized microcirculatory 
vessel constriction and underperfusion of the vascular bed should 
not be underestimated. 
The inflammatory reactions involved in HAR are obviously 
remarkably complex. Furthermore, they are surprisingly resilient 
and redundant in their organization, so that the same set of 
functions can be executed through many alternative backup 
systems. Consequently, even if the potent biologic activities of 
one specific mediator could be totally blocked by highly specific 
antagonists, which has yet to be completely achieved, the 
combined release of other inflammatory and biologically active 
agents could easily replace the functions of the missing agent 
and mediate an unwanted process. An understanding of these 
complexities have very important implications for the therapeutic 
approach to HAR. 
The pathogenesis of hyperacute rejection for the kidney and 
the heart has been extensively investigated and fairly well 
established. The causal event of an antibody mediated injury 
(IgG and 19M) to the vascular endothelium (16), which is 
propagated by secondary vasoconstriction (17), the recruitment of 
polymorphonuclear leukocytes (18), and aggregated platelets 
(19,20), then followed by intravascular coagulation (19-21). The 
combinat ion of vasoconstr ict ion and the platele t-Ieukocyte-plug s 
occlude the small arterioles and capillaries inducing ischemic 
necrosis of the organ. It is tentatively proposed that the 
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J recruitment of leuKocytes and platelets is initially due to 
immune adherence and specific aggregation and later due to stasis 
and nonspecific entrapment. This entire process is accompanied 
by fibrin deposition and rarid total destruction of the vascular 
system of the organ (2,8). The pathologic description of this 
entity today, remains exactly the same as the original 
descriptions (22), and in fact, at that time the similarity of 
hyperacute rejection of the kidney to the events of the 
experimental generalized Shwartzman reaction was suggested (2). 
After the binding of antigraft antibody to antigens on the 
endothelium, all of the events that occur thereafter are 
immunologically non specific, namely, activation of clotting, 
fibrin deposition, fibrinolysis, capillary leaking and the influx 
of inflammatory cells with their own release of mediators, and 
finally injury to the renal parenchyma The process of hyperacute 
rejection involves most, if not all, of the components of the 
typical inflammatory response (23). Obstruction of the small 
arteries by the platelet-neutrophil-plugs induces an accompanying 
ischemia in cells which may activate the complement system by the 
alternate pathway. The release of the vasoactive substances C3a 
and C5a results in enhanced inflammation with neutrophil 
margination and migration to the damaged tissue. This results in 
neutrophil activation, with a burst of oxygen consumption and the 
production of oxygen derived free radicals. The activation of 
neutrophils leads to an increase in phospholipase A2 activity 
which releases arachidonic acid from membrane phospholipids (23). 
8 
1 A cascade is thus begun which produces a large number of 
biologically active lipid products which include the 
prostaglandins, leukotrienes and thromboxanes. Two of the more 
important lipid mediators include leukotriene Bl which is a very 
potent neutrophil chemoattractant and thromboxane A2 which is an 
extremely potent vasoconstrictor, and platelet pro-aggregator. 
Thus, the many arms of the inflammatory process come together to 
create a relentless and mutually perpetuating progression 
resulting in organ destruction • 
• 
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1 III. THE POTENTIAL ROLE FOR PAP AND ITS ANTAGONISM IN BAR 
Platelet-activating factor (PAP) is a potent mediator of 
many inflammatory reactions because of its broad range of 
biological activities as outlined in this test. PAP is released 
by many cell types including the endothelium, and can also affect 
different cell types. It can be mediated by immunologic as well 
as non-immunologic stimuli (24). PAP can evoke almost all the 
well-known cardinal signs of acute inflammation and probably 
plays a central role in the induction of tissue injury (25). The 
biological effects of PAP, which include platelet and neutrophil 
aggregation and activation, increase in vascular permeability, 
smooth muscle contraction and the release of numerous vasoactive 
and potent biological mediators, can influence the 
microvasculature of all organs and therefore must be considered a 
key participant in the disruption of microvascular flow. There 
is already considerable evidence for the candidacy of PAP as a 
central and key biologic mediator in the pathogenesis of 
humorally-mediated hyperacute allograft rejection. 
In vitro studies have demonstrated that PAF is released when 
endothelial cells are incubated with antibody to cell surface 
angiotensin converting enzyme. This has important implications 
for hyperacute rejection, in which the specific initiating event 
is a transplantation antigen-antibody interaction on the 
endothelial surface. In a model of hyperacute renal allograft 
rejection in sensitized rabbits, PAF was identified in the blood 
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effluent from the transplanted kidney, following immediate 
antibody and complement fixation to the endothelium of glomerular 
and peritubular capillaries (26). No PAP could be detected in 
rabbits without clinical or histologic signs of hyperacute 
rejection (i .e., there was nc PAP release in syngeneic controls 
or renal allografts transplanted into unsensitized recipients). 
The PAF release was detected within 2 to 10 minutes after 
revascularization and was followed by the recruitment of 
platelets, endothelial sticking, and obliteration of capillaries 
by platelet-PMN plugs and evidence of cellular degranulation 
(26). Whether PAP was released from the endothelial cells of the 
graft or from the inflammatory cells infiltrating the organ was 
not determined. 
The importance of PAP, even in the absence of inflammatory 
cells, was demonstrated in a model of ex vivo perfusion of the 
rabbit heart with transplantation alloantibod ies (27). The 
release of PAF followed bradycardia, conduction arrhythmias, 
decreased coronary flow, and cessation of heart action. These 
alterations in cardiac function and, moreover, the release of 
PAF, were prevented by complement inactivation. PAF itself 
induced a negative inotropic effect and reduction of coronary 
flow in isolated guinea pig heart muscle by a direct action on 
the CA ++ slow channel. Moreover, the injection of synthetic, 
purified PAF into the renal artery of rabbits reproduced a 
pathologic picture identical to that seen in a Shwartzman 
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J reaction of the kidney. The pathophysiology of hyperacute renal 
rejection in hunians was originally described as a Shwartzman 
r e ac t ion (2). 
The nonspecific effector inflammatory cascade that ensues 
once an antigen-antibody reaction has initiated hyperacute 
rejection has served as the target for therapeutic intervention 
by many different approaches. Classically, the platelet-
coagulation system has been considered to be the most important 
and has received the greatest attention. These therapeutic 
modalities have included heparin, aspirin, dextran, citrate, 
defibrinating agents, cobra venom factor, induction of 
thrombocytopenia by antibodies etc., and various prostaglandins 
(28-30). All these approaches have been either too toxic or the 
results too inconclusive to be accepted for generalized use. 
The difficulty in overcoming the inflammatory process in 
hyperacute rejection and in explaining the discrepancies in 
therapeutic results rest not only in the complexity of the 
biologic reactions, but also in their resiliency and redundancy. 
That is, there are numerous alternative mediator pathways that 
c an back up the same set of func t ions. Thus, the inh ib i t i on of 
one arm of an inflammatory reaction can easily be replaced by the 
release of other inflammatory autocoids with complete mediation 
of a disease process. PAF may represent somewhat of an exception 
to this hypothesis, because of its potency and its unique 
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J potential for mediating almost every aspect of acute inflammatory 
reactions. Nonetheless, the argument for polypharmaceutical 
therapy of hyperacute rejection appropriate. 
With the availability of specific receptor antagonists of 
PAF, further insight into the role of PAF in the pathogenesis of 
HAR is now possible. The potential for a new method of 
controlling the effector cascade of HAR by pharmacologic 
intervention can now also be exploited. 
A number of PAF acether antagonists have been reported to 
block PAF binding to its high-affinity receptor and their 
application has been documented in various pathological 
conditions. Included in these disease states are the 
inhibition/or reversal of PAF-induced hypotension (31,32), 
neutropenia (33), bronchospasm (34,35), endotoxic shock (36), and 
anaphylaxis (37) in animal models. 
There has been little evidence to date that PAF antagonists 
are capable of preventing or diminishing the phenomenon of 
antibody-mediated BAR. In the model described previously of the 
rabbit heart perfused ex vivo with transplantation 
alloant ibod ies, PAF was released in the absence of in flammatory 
cells. The addition of a PAF receptor antagonist, SRI 63-072, 
(Sandoz Company) prevented the reduction of coronary flow by 70% 
within 2 to 4 minutes after its addition to the perfusate. In 
this model, heart action was prolonged after the addition of SRI 
63-072, however, eventual hyperacute rejection was not prevented. 
Implications that PAF may also contribute to cell-mediated 
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J cardiac allograft rejection have also been reported by Foegh et 
a1. (38). A slight but significant prolongation of rat 
heterotopic heart allograft ~as achieved following ad~inistration 
of a PAF-receptor antagonist, BN52021 (Henri Beaufour Institute, 
Paris, France), in nonsensitized recipients. The current study 
evaluates two types of invivo models of HAR, namely, in the 
hypersensitized recipient and in xeno transplantation. These 
studies not only lend further support to the prominent role of 
PAF in the regulation of the inflammatory response leading to 
hyperacute rejection, but also introduce a new and potentially 
significant therapeutic approach to this entity. The agent used 
in all of these studies, SRI 63-441, is specific PAP receptor 
antagonist manufactured by the Sandoz Company (East Hanover, New 
Jersey). It represents a family of compounds that can be 
synthesized and modified to meet desired specifications, i.e., an 
oral compound recently has been produced. 
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IV. THE bcc~q OF SRl 63-441 ALONE AND IN COMBINATION 
WITH IMMUNOSUPPRESSION ON EXPERIMENTAL CARDIAC 
HYPERACUTE REJECTION IN PRESENSITI ZED RECIPIENTS 
A. BACKGROUND 
Ex per i men tal stu die s tar get ed to in ve s t i gat e HA R 0 f he art 
and renal allografts originally utilized non-inbred models, 
primarily the dog (20,39). The genetic composition of these 
combinations were generally unknown and despite calculated donor-
specific presensitization, HAR was not consistently achieved 
(40). Moreover, these experiments could not be adequately 
controlled with syngeneic pairs without the interference of 
rejection. Data derived from these investigations must therefore 
be cautiously transferred to the clinical setting, as separate 
examiners were inclined to emphasize alternate morphologic 
features as being characteristic or central to this process 
(21,41). While the rat would appear to be a logical model of 
choice for investigating these issues, it was previously thought 
not to possess an adequate complement system in order to mount 
such a response. Guttman and colleagues (42) first demonstrated 
that HAR of heterotopic heart allografts could be regularly 
produced in specific inbred rat strain combinations without 
necessitating an exogenous source of complement or direct graft 
infusion. These donor-recipient combinations were selected on 
the basis of a strong histocompatibility barrier. The 
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J establishment of the sensitized rat as a suitable model for 
experimental HAR is a particularly impressive finding in that 
controlled investigations designed to elucidate the mechanism(s) 
of HAR could be undertaken. Further investigations have 
described the importance of immunization across the MHC in rats 
as essential for the induction of HAR, with particular reference 
histocompatibility antigens (Class I) encoded by the RTl.A locus. 
Complement components were also deemed essential for this 
response as C3 depleted recipients failed to reveal functional 
and pathological changes generally associated with HAR. 
Moreover, the rat has been well defined genetically and there 
exists a high degree of homology between the MHC of man and rat. 
B. MATERIALS AND METHODS 
Animals 
Commerc ially available inbred male Lewis (L) (RTll) and 
ACI (RTl a ) rats weighing 200 to 220 grams were purchased from 
Harlan Sprague Dawley, Indianapolis, Indiana. This strain 
combination was selected on the basis of a strong 
histoincompatibility to provide a reproducible and reliable model 
of hyperacute rejection (42). Rats were acclimatized in the 
central animal facility for at least two weeks prior to 
investigation and received standard rat chow and water ad 
libitum. 
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J SURGICAL PROCEDURES 
Skin Grafting 
Presentation of L recipients was carried out under 
methoxyflurane anesthesia by removing full thickness ventral 
abdominal skin from ACI donor rats. A 2.5 cm circular skin graft 
was transplanted to the dorsum of the Lewis recipient and 
fastened with Clay Adams wound clips. Casting material was then 
applied for 4 days after the grafting procedure to immobilize the 
tissue. Grafts were evaluated visually for rejection. A second, 
third and fourth graft were placed at intervals of 14 days in a 
similar manner. 
Heterotopic Heart Transplantation 
Heterotopic heart transplants were performed 17-20 days 
following the fourth skin graft. Contemporaneous controls 
(sodium acetate buffer only) were performed for each experimental 
group. 
Animals were anesthetized with 40 mg/kg sodium pentobarbital 
IP and supplemented with methoxyflurane. Surgical procedures for 
the primarily vascularized cardiac transplants in rats have been 
well described previously (43). Briefly, an end-to-side 
anastomos is is per formed between the donor and rec ip ien t aor ta, 
as well as the donor pulmonary artery to recipient vena cava. 
Impulses of the transplanted hearts were monitored every 30 
minutes for the initial 15 hours, and then twice daily thereafter 
17 
J by palpation through the recipient abdominal wall. Rejection was 
considered complete when there were no palpable contractions and 
confirmed visually at laparotomy and by histological evaluation. 
All experimental animals were weighed daily. 
PHARMACOLOGIC ADMINISTRATION 
PAl' AntaSl on is t 
SRI 63-441: The receptor-specific antagonist of PAF, SRI 
63-441, was supplied by Sandoz Research Institute (East Hanover, 
New Jersey), and its properties and pharmacology have been 
described elsewhere in this text. The powdered form was 
reconstituted in 0.68% sodium acetate buffer and 0.9% sodium 
chloride (pH 5.3) to a final concentration of 10 mg/ml, and 
placed in a warm water bath (26-280 ) for 5 minutes. A single 
bolus injection was administered via the inferior vena cava at 
four minutes pr ior to revascular ization. The dosages evaluated 
are listed in the individual tables. 
Immynosuppression 
FK 506: FK 506 has strong immunosuppressive activity 
against mixed lymphocyte reactions (44), suppresses T cell-
mediated injury (perhaps by suppressing both interleukins 2 and 
its receptor expression on T cells) and has been reported to 
inhibited rejection of heterotopic heart transplants in rats 
(45). Crystalline powder FK 506 (MW 882) was supplied by 
Fujisawa Pharmaceutical Company, Ltd, (Osaka, Japan). A final 
18 
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J concentration of 1.28 mg/ml was prepared in 0.9% sodiurr. chloride. 
FK 506 was administered at a dosage of 1.28 mg/kg/day for a 
duration of 14 days (or until rejection) by intramuscular 
injection commencing three days prior to transplantation. 
C y c los P 0 r i n e ( C sA) : A com me r cia 11 y a va i 1 a b Ie C sA 
formulation of 100 mg/ml (Sandoz Company) was diluted in olive 
oil to a final concentration of 10 mg/ml and administered orally 
at a dosage of 15 mg/kg/day commencing 3 days prior to 
transplantation and for a duration of 14 days (or until 
re jec t ion) • 
Antibody Titers 
A 0.5 m1 blood sample was obtained under methoxyflurane 
anesthesia from the inferior vena cava immediately prior to 
revascularization of the transplanted organ. A complement-
dependent-cyto1ytic assay (CDC) was performed to access antibody 
titers. 
C. RESULTS 
SRI 63-441 Alone 
Cardiac allograft survival for control and SRI 63-441 alone 
treated animals is summarized in Table I. Control Lewis rats 
that had been previously sensitized by ACI strain skin grafts and 
then received ACI donor hearts, consistently rejected these in a 
hyperacute fashion (MST 237 minutes ± 47.4 n=60). Treatment of 
sensitized rats with SRI 63-441 alone as a single intravenous 
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J bolus prior to revascularization resulted in a varied response. 
Significant prolongation of graft survival was achieved in 
animals treated with 15 mg/kg of SRI 63-441 (MST 2403 minutes ±. 
542, P < 0.001 n=20) as compared to controls. In fact, 9 of 
these hearts functioned from 2 to 5 days following 
transplantation. 
these rats. 
There was no significant change in weight in 
Histological EvaluatioD 
Tissue sections stained with H+E were reviewed without 
knowledge of treatment protocols. The morpholog lcal features 
which were considered diagnostic of cardiac hyperacute rejection 
included extensive interstitial hemorrhage, occlusion of vessels 
by platelets, endothelial cell damage and myocyte necrosis 
(Figure 1). Polymorphonuclear cell infiltration was not a 
constant feature. These histologic features were evident in all 
control rats. 
Heart allografts that functioned long term (i.e., 2-4 days) 
and then ceased to function exhibited an entirely different 
histologic picture. Sections froIT. these hearts exhibited an 
abundant mononuclear cell infiltrate, many of which demonstrated 
features of blast formation (Figure 2). This finding was 
interpreted as acute cellular rejection. Typically, there was 
much less interstitial hemorrhage and little or no platelet 
plugging of vessels noted. Myocyte degeneration and fibroblast 
20 
J proliferation were frequently extensive. No overlap with 
hyperacute rejection was recognized. The native hearts of the 
animals in all groups were consistently without morphologic 
change. 
SRI 63-441 and Immunosuppression 
Animals pretreated with multiple administration either CsA 
alone or in combination with SRI 63-441 failed to demonstrate a 
beneficial effect (Table II). A slight but significant 
prolongation of allograft survival was evident when a single dose 
of CsA was administered at 6 hours prior to transplantation (1523 
minutes ±. 566 versus 237 minutes ±. 47.4 P < 0.05). 
As evident in Table III, treatment with FK 506 alone pr ior 
to transplantation resulted in increased graft survival time. Of 
even greater significance was the response in cardiac allograft 
survival observed when SRI 63-441 treatment (at 2 dosage levels) 
was combined with immunosuppression by FK 506. In several cases, 
graft survival either approached or exceeded one month. 
In general, level of circulating antidonor antibodies did 
not correlate well with organ graft rejection times. This 
observation is analogous to that experienced clinically at this 
time. It is now generally accepted that tests for antibodies 
before and after transplantation must be perfected with ,further 
emphasis placed on a distinction between deleterious, beneficial 
and insipid antibodies (46). 
21 
J HistolQgic Evaluation 
The extent and quality of the mononuclear infiltrate 
observed in the grafts of those animals treated Iodth SRI 63-441 
alone and SRI 63-441 and FK 506 (Figure 3) was quite different: 
The grafts of those animals treated with SRI 63-441 alone 
contained a more abundant mononuclear cell infiltrate, many of 
which exhibited features of blast for~ationK Photomicrographs of 
myocardial sections from animals treated with SRI 63-441 and FK 
506 generally exhibited features of mild acute cellular 
rejection. 
D. SUMMARY 
Since the original description of hyperacute rejection of 
the kidney, numerous experimental and clinical studies have 
attempted to define the precise mechanism(s) of this destructive 
process. While our interpretation of HAR has advanced, one must 
recognize this phenomenon as multifactorial and the product of a 
complex immune/inflaITur.atory reaction. Platelet-activating factor 
has been proposed as a key biolog'ical cand idate in the overall 
evolution of this type of inflammatory process and as a central 
mediator in the pathogenesis of antibody-mediated hyperacute 
rejection. In a model of heterotopic cardiac transplantation 
into sensitized rats, we were able to demonstrate that the 
phenomenon of hyperacute rejection previously thought to be 
refractory and uncontrollable, could be converted into a 
potentially more manageable form of classic rejection by a single 
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J bolus adn.inistration of a PAF antagonist, SRI 63-441, prior to 
revascularization. Indeed, hearts in treated animals that ceasea 
to function at two to four days after transplantation 
demonstrated a very aggressive histological picture of acute 
cellular rejection with marked ederr.a and extensive mononuclear 
cell infiltration. This suggested the prospect of adding classic 
immunosuppression in an attempt to overcome the cellular 
rejection. 
It was clear that very potent immunosuppression would be 
required because the cellular rejection of hearts in the SRI 63-
441 treated animals was much more aggressive and was occurring 
much earlier than is usually seen in the same donor-recipient 
combination without prior sensitization. This probably reflects 
the aggressive rejection of an organ made vulnerable by antibody 
attack. The combination of FK 506 and SRI 63-441 treatment in 
this model of hyperacute cardiac rejection resulted in remarkable 
prolongation of graft survival in healthy animals. The survival, 
for the most part, far exceeded the allograft survival in 
nonsensitizea recipients (6.3 ±. 0.5 days) and in several cases, 
graft survival either approached or exceeded one month survival. 
These studies provide further insight into the complex 
immunologic ana inflammatory reactions involved in the process of 
hyperacute rejection. Moreover, we introduce a novel and 
23 
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combined attack on the very potent and unusually diverse spectrum 
of biologic activities of a key inflammatory mediator as well as 
on a very aggressive form of classic cell-mediated rejection. 
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V. 'THE EFFECT OF SRI 63-441 ALONE ARD IN CC»(BlNATION WITH 
PROSTANOIDS ON EXPERIMENTAL IENOTRANSPLANTATION 
A. BACKGROUr.ro 
Pig-to-aog renal heterotransplantation results in a rapid 
and violent form of cortical necrosis and ischemic destruction of 
the organ, which mimics the situation in humans and is due to 
preformed humoral antibodies in the recipient (19,20). It 
represents an appropriate severe model in which to evaluate new 
methods of therapeutic intervention. The studies reported 
evaluated the effect of a novel and potent synthetic PAP receptor 
antagonist, SRI 63-441, alone and in combination with other 
prostanoids, on this renal xenograft model. 
B. MATERIALS AND METHODS 
Animals 
Female, white outbred SPF pigs that weighed 15-20 kg were 
purchased from Shadyside Farms, Ohio and served as donors. Male 
beagles that were bred for research and weighed 13-16 kg were 
purchased from Laboratory Research Enterprise, Kalamazoo, 
Michigan and served as recipients. All animals were housea in a 
central animal facility and were allowed to acclimatize for at 
least 1 week before exper imentation. They received standard 
animal chow and water ad libitum and were fasted for 24 hors 
before surgery. 
25 
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Qrthotopic Renal Transplantation 
All ani~als for both the donor and recipient procedures were 
anesthetized with intravenous sodium pentobarbital (30 mg/kg). 
Recipient dogs were maintained with 30% oxygen through an 
endotracheal tube. Additjonal anesthetic (pentobarbital, 3 mg/kg 
IV) was given as required. 
Donor pigs received intravenous Ringer's lactate (1000 mL), 
mannitol (12.5 g), and Thorazine R (50 mg). After systemic 
heparinization (5000 units) and in situ cooling with cold (4 C) 
Ringer's lactate through an aortic cannula, the kidneys were 
removed en bloc. The kidneys were then separated and 
transplanted simultaneously into two recipient dogs, always with 
less than 1 hour of cold ischemia time. A paired design was 
therefore performed for each experiment, by assigning one kidney 
as the control and the other as the test (treated) kidney. 
All pig-to-oog kidney heterotransplantation were performed 
by a standard technique. The porcine renal artery was 
anastomosed end-to-end to the recipient right common iliac 
artery, and the renal vein was anastomosed end-to-side to the 
right common iliac vein. The anastomosis time was always less 
than 30 minutes. The ureter was cannulated with polyethylene 
tubing and urine was collected throughout the transplant period. 
For intra-arterial administration of prostaglandins, an l8-gauge 
polyethylene catheter was inserted through the middle sacral 
artery and threaded towards the orifice of the right common iliac 
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J artery. To ensure that solution infused into the terminal aorta 
would exclusively run into the graft renal artery, the left 
common iliac, middle sacral, and other smaller arteries 
originating at our near the aortic bifurcation were ligated near 
their origin. For those experiments where renal vein and artery 
platelet counts were measured, IS-gauge polyethylene catheters 
were introduced into the right femoral vein and its tip 
positioned at the venous anastomosis, and into the left common 
iliac artery and its tip positioned at the orifice of the right 
common iliac artery. 
Each dog underwent native nephrectomy after the porcine 
kidney had been revascularized. A change in color or mottling of 
the transplanted pig kidney was considered evidence of the onset 
of rejection. However, the end point of the experiment was 
signaled by a cessation of ur ine flow or by the onset of frank 
hematuria. 
moA~~ClildfC ADMINISTRATION 
mrosta~landins: Naturally occurring prostacyclin (PGI2) and 
prostaglandin El (PGEl) or Prostin-VR were supplied by the Upjohn 
Company, Kalamazoo, Michigan (M.J. Ruwart). PGI2 was 
reconstituted and infused in a 0.1 M glycine buffer, adjusted to 
a pH of 10.5 with 2 M Tris solution to enhance its stability. 
PGEI was reconstituted in a stock solution of 1 mg in 100 uL of 
ethanol. This solution was then diluted to the appropriate 
concentration in 0.9% sodium chloride for infusion. 
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exper iment, were administered by constant infusion through the 
catheters placed into the aorta I ar.d the dosage was titrated 
according to blood pressure tolerance. Control animals for the 
prostaglandin experiments received infusions of the particular 
prostaglandin vehicles. 
PAr Antagonist: SRI 63-441 was provided by the Sandoz 
Research Institute, Sandoz, Inc. (East Hanover, NJ). For all 
studies reported here SRI 63-441 was reconstituted as a 10 mg/mL 
solution in 0.68% sodium acetate and 0.9% sodium chloride (pH 
5.3). Before its administration, this solution was placed in a 
warm water bath (24-25 C) for 5 minutes and then administered as 
a bolus intravenous injection. Control dogs received the sodium 
acetate buffer intravenously. 
Experimental Design 
Four experimental groups are reported: Group I: the 
administration of SRI 63-441 alone was compared with controls: 
Group II: the combination of SRI 63-441 and PGI2 was compared 
with controls: Group III: the combination of SRI 63-441 and 
PGEI was compared with controls; Group IV: the combination of 
SRI 63-441 and PGEl was compared with PGEl alone. 
Both prostaglandins (PGI 2 , PGE1) were administered at a dose 
of 0.5-1.0 ug/kg/min (depend ing on systemic blood pressure) by 
continuous intra-arterial infusion commencing at 30 minutes 
before revascularization. SRI 63-441 was administered at 5 
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J mg/kg/dose by intravenous bolus beginning at 5 minutes before and 
then 5 minutes after, and then every 15 minutes after 
revascularization. For each study, experiments were performed on 
control and test animals simultaneously. 
Kidney survival was assessed for each experiment as 
described above. Urine was collected for the entire transplant 
per iod, and the total volume was used as an indicator of renal 
function. For six experiments in Group II and for three 
experiments in Group IV, platelet counts in the renal artery, 
renal vein, and per ipherally were determined ser ially (every 10 
minutes for the first hour and then every 30 minutes for up to 4 
hours in the treated groups). Serial kidney biopsies (every 15 
minutes) were performed in an extra group of animals that are not 
included in survival statistics. Biopsies were also done at the 
end point of the experiment, (using the criteria outlined above) 
in all groups studied. 
c. RESULTS 
Renal ueno~raft Survival 
Figure 4 depicts the survival for transplanted porcine 
kidneys in the four groups studied. The control dogs in all 
experiments consistently demonstrated violent rejection of the 
pig kidney within a mean time of approximately 30 minutes. The 
administration of SRI 63-441 as a single agent at the dosage and 
schedule described here did not result in a significant increase 
in graft survival. The addition of either prostanoid (PGI2 or 
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J PGEl) to SRI 63-441 treatITIent resulted in a marked synergisIT: and 
a significant increase in kidney survival. SRI 63-441 and PGI2 
resulted in a greater than six fold (217.1 ±. 39.4 versus 37.4 ±. 
11.1 minutes, p < 0.001) and SRI 63-441 and PGEI in a greater 
than seven fold (268.6-± 27.7 versus 37.2 1. 5.6 minutes, p < 
0.001) increase in renal xenograft survival when compared with 
their respective controls. PGI2 or PGEI infused as single agents 
had no significant effect on kidney survival. In fact, in Group 
IV, the combination of SRI 63-441 and PGEI resulted in a greater 
than nine fold increase in kidney survival when compared with 
PGEI infusion alone (280.4 ± 31.8 versus 31.0 1. 11.1 minutes, p < 
0.001). PGEI in this experiment behaved no differently than the 
control vehicles in the other experiments. 
Renal Xenograft Function 
Renal function as determined by total urine output for each 
transplant is depicted in Figure 5. The results parallel those 
observed for kidney survival already presented above. SRI 63-441 
alone did not significantly improve renal function. The 
combination of SRI 63-441 and PGI2 resulted in a greater than 
threefold (99.5 ±. 30.4 versus 29.5 ± 13.7 roL, p < 0.05) and of 
SRI 63-441 and PGEl in a greater than 20-fold (436.2 ±. 134.8 
versus 21.2 ±. 7.3 mL, p <0.02) increase in total urine output. 
Neither prostanoid alone resulted in a significant increase in 
urine output. The combination of SRI 63-441 and PGEl 
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J resulted in a 12-fold increase in total urine output (370.9 ±. 
78.9 versus 32.7 ±. 6.4 mL, p <0.003) when compared "dth PGEI 
alone, which did not differ significantly from vehicle controls. 
Platelet Studies 
The serial platelet counts for six experiments in Group II 
(SRI 63-441 + PGI2 versus controls) and three experiments in 
Group IV (SRI 63-441 + PGEI versus PGEl) are depicted in Figures 
6 and 7, respectively. There was a significant difference 
between the renal artery and renal vein platelet counts in Group 
II for both control and treated animals, with a more pronounced 
gradient evident in the control group. No significant gradient 
in platelet count between renal artery and vein was observed in 
Group IV dogs. 
Histological Eyaluation 
Microscopically, in the serial experiment, baseline biopsies 
from both control and treated animals contained normal glomeruli, 
with normal cellularity, and patent, empty capillary loops. 
After reperfusion, both kidneys exhibited progressive 
obliteration of capillary loops by eosinophilic granular material 
mixed with red blood cells. Similar thrombi were found in 
arteries and arterioles as early as 15 minutes. Tubules remained 
well preserved until I hour. There was progressive edema, then 
congestion, then hemorrhage in the interstitium. At the 
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J endstage, ""hen renal function ceased, all specirr,ens showed 
diffuse thrombosis of glomeruli, arteries, and vasa rectae. 
There were interstitial hemorrhages and early changes of ATN. 
Sequential Biopsies: Biopsy specimens were taken at 5, 45, 
and 90 minutes. Qualitatively, the glomerular changes were 
sindlar in the control and treated groups. However, the 
development of glomerular thrombosis proceeded at a slower rate 
in the treated kidneys. Table IV shows the results from one 
experiment. The control animal reached end-stage with thrombosis 
in 94% of the glomeruli at 45 minutes, ""hereas the process 
reached completion in the treated kidney at 90 minutes. At 
endstage, red blood cell thrombi were more prominent in the 
treated kidney. 
Necrosis of tubular epithelial cells was noted in the 
control kidney with blood in the lumens at 60 minutes. 
change persisted until the end of the experiment. 
These 
I t is 
important to note that significant necrosis was not noted in the 
treated kidney. 
There was a difference between the two kidneys in the amount 
and onset of interstitial hemorrhage. Focal hemorrhages ""ere 
noted in the control kidney at 15 minutes~ this progressed to 
diffuse hemorrhage by 45 minutes and persisted. In contrast, the 
treated kidney showed only focal hemorrhages at 30 minutes, and 
again at 90 minutes. There ""ere no significant differences 
between the control and treated kidneys with regard to the 
presence of thrombi in arteries and arterioles. 
32 
J Endstage Biopsies: The endstage biopsies obtained after 
implantation represented a later stage than the sequential 
biopsies. In these sections, RBCs were a prorrinent component of 
the glomerular thrombi in the treated kidneys, whereas in the 
control groups the thrombi were composed of mostly granular 
eosinophilic material consistent with platelet-fibrin thrombi, 
similar to the changes noted in the sequential biopsies. There 
was more interstitial hemorrhage in the treated dogs than in the 
controls in five cases, and less hemorrhage in four cases. Three 
of the treated kidneys and none of the control kidneys exhibited 
up to 20% glomeruli free of thrombi. 
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J VI. THE EFFECT OF SRI 63-441 ON CAT-TO-RASBIT RENAL 
XENOTRANSPLARTATION 
A. MATERIALS AND METHODS 
Animals 
Female, purpose bred for research cats that weighed 4.0-5.0 
kg were purchased from Liberty Labs, Liberty Corner, NJ, and 
served as donors. Female Checkered Flemish giant rabbits 
weighing 4.0 to 6.2 kg were purchased from Zivic Miller Labs, 
Allison Park, PA, and served as recipients. All animals were 
housed in the central animal facility and were allowed to 
acclimatize for at least one week prior to experimentation. They 
received standard animal chow and water ad libitum and were 
fasted for 24 hours before surgery. 
SURGICAL PROCEDURES 
Orthotopic Renal Transplantation 
Donor bilateral nephrectomy was performed en bloc taking the 
aor t a, vena cava, renal vessels and ureter s. The kidneys were 
flushed in situ, through an infrarenal aortic cannula, with 400-
500 cc of cold (4 oC) Ringers Lactate. Each donor provided 2 
kidneys for transplantation: Control versus SRI 63-441 treated. 
In the rec ipient, the left lumbar fossa was prepared for 
anastomosis. Orthotopic kidney transplantation was then 
performed by anastomosing the renal veins using a microvascular 
cuff technique, and the renal arteries by an end-to-side aorta-
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J The ureters were cannulated with a 20-22 gauge catheter and 
approxiffiated to the skin for urine collection. 
PHARMACOLOGIC ADMINISTRATION 
SRI SP~ was prepared in an identical manner as described 
in the previous section and administered as a single intravenous 
bolus beginning 5 minutes before revascularization and at a 
dosage of 4 mg/kg. Controls received the drug buffer 
intravenously. 
~xperirnental Design 
A total of 15 control procedures were preformed. SRI 63-441 
was administered to an additional 6 rabbits. Each animal treated 
with SRI 63-441 had a paired control procedure performed at 
exactly the same time. 
B. RESULTS 
Renal xenograft survival as determined by kidney color, 
consistency and cessation of urine formation: and function as 
measured by urine output are given in Table V, for both groups 
studied. The urine output of treated animals at one and two 
hours after revascularization was significantly better than in 
untreated controls, in fact, controls in this model consistently 
produce very little, if any urine. Although the biological 
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observed in treated animals is not completely apparent, the 
results were statistically significant. 
Histological Eyaluation 
Representative histologic sections from these experiments 
are presented in Figure 8 (Control), and Figure 9 (SRI 63-441 
treated). In the control animals, all except one kidney showed 
normal glomeruli and varying degrees of tubular vacuolization, or 
ATN prior to 40 minutes. 
In the one animal 10-14% of the glomeruli in each of the 
kidneys in different recipients contained thrombi by 30 minutes. 
At 40 minutes glomerular thrombosis ranged from 2 to 8%. In end-
stage specimens taken at I hour or later, the percentage 
glomerular thrombosis ranged from 2 to 14%, so it appeared that 
the end-stage was reached between 40 and 60 minutes. Eosinophils 
were frequently noted in all specimens. Polys and necrosis were 
seen in only one specimen. 
Kidneys from animals receiving SRI 63-441 showed only mild 
tubular vacuolization at one hour, compared to overt ATN in the 
control kidneys. At 1 1/2 hours both kidneys were the same, with 
at most 3% glomerular thrombosis and ATN. 
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J VII. SOMM.AR! 
At the single dosage and schedule of SRI 63-441 evaluated in 
these studies, inhibition of PAF alone was not sufficient to 
irr.prove renal xenograft survival or function in the pig-to-dog 
model, although a trend did exist, but did significantly improve 
these parameters in the cat-to-rabbit model. These findings may 
have some implication into a better understanding the process and 
biology of EAR in different species combinations. From studies 
in rats and other recent studies in dogs, we have determined that 
the critical consideration for the efficacy of SRI 63-441 is to 
administer it at a much higher dose and before revascularization. 
However, the addition of either one of two prostanoids, PGI2 or 
PGE1, resulted in a synergistic response and a manyfold increase 
in renal xenograft survival and function in the pig-to-dog model. 
Although a higher dosage and more appropriate scheduling of SRI 
63-441 may improve the effectiveness of single drug therapy, the 
need for multiple drug treatment eluded to above may be necessary 
to adequately modulate this violent inflammatory process. 
There are many reasons for choosing PGI2 and PGEl as 
c ompl imen tar y agen ts to SRI 63- 441. They both inh ib i t pIa tele t 
function by stimulation of receptor-coupled adenylate cyclase and 
increase intracellular cAMP, a receptor mechanism different from 
that required for SRI 63-441 inhibition (47). To varying 
degIees, they both exhibit other properties that establish them 
as excellent therapeutic candidates for such inflammatory 
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) processes. These biological activities include vasodilatation, 
fibrinolytic action, inhibition of the generation of certain 
deleterious metabolites of the arachidonic acid cascade, 
inhibition of oxygen-free radical generation, and the property 
known as cytoprotection (47). Moreover, both these 
prostaglandins have been evaluated in other models of hyperacute 
rejection. Treatment with PGEl prolonged hamster-to-rat cardiac 
xenograft survival (48). PGI2 administration significantly 
prolonged kidney survival in both a model of hyperacute renal 
allograft rejection in presensitized dogs and in cat-to-dog 
xenografts (30,48) but had no effect on guinea pig-to-rat cardiac 
xenograft survival (48). Neither PGI2 nor PGEl, when 
administered alone as a constant infusion without combination SRI 
63-441 treatment, had a significant effect on pig-to-dog renal 
xenograft survival or function as described in our studies. 
Furthermore, the therapeutic effectiveness of these 
prostaglandins in combination with SRI 63-441 was evident only 
when they were infused intra-arterially; peripheral 
administration of prostaglandins did not exhibit synergism with 
SRI 63-441 (unpublished results). This is most likely due to 
inactivation of prostaglandins as they pass through the lungs 
(47) • 
The pig-to-dog renal xenograft model evaluated in these 
studies probably represents the most severe animal model of 
hyperacute rejection known. Rapid and violent kidney rejection 
is the rule and there have been only a few reports of successful 
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abrogation of this process. Shons and Najarian reported a 
significant increase in pig renal xenograft survival from a mean 
of 5 min ute sin con t r 01 sup to a mea n 0 f 4 5 IT! in ute sin dog s 
treated with a variety of antiplatelet agents (29). Merkel et 
ale reported renal xenograft survival times of 120, 90, and 180 
minutes in three dogs that had preoperative plasmapheresis (49). 
Kux et al. reported a mean rejection time of 85 minutes in 15 
kidneys treated with intra-arterial citrate infusion; these 
experiments were lirr.ited by significant toxicity (50). The 
control xenografts for the latter two sets of experiments 
rejected in less than 10 minutes (20,49). 
Cons istent and reproduc ible results were achieved in the 
same model in the current studies by combining SRI 63-441 with 
either PGI2 or PGE2. Pig kidneys surviving for 3-4 hours were 
consistently achieved with maintenance of good urine output in 
all combination treatment groups. There were three kidneys in 
this series of experiments that functioned satisfactorily for 6-9 
hours. The results in the cat-to-rabbit model, although less 
stl ik ing, were sign i f icant and further emphasis that this 
phenomenon is not species specific. 
CONCLOSIONS 
These studies further confirm the central role of plate-
activating factor in the inflammatory cascade that destroys 
hearts and kidneys undergoing hyperacute rejection. Furthermore, 
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J these studies introduce a novel, reproducible, and potentially 
effective therapeutic approach to this difficult problerr., which 
relies on a better understanding of the basic pathophysiologic 
process of inflammation and which utilizes as its basis, a 
synthetic receptor antagonist that specifically inhibits the 
potent and unusually diverse spectrum of biologic activities of 
one of the key mediators of classical inflammation. 
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TA8LE 1 
THE EFFECT OF SRI 63-441 ON CARDIAC ALLOGRAFT SURVIVAL IN PRESENSITIZED 
RECIPIENTS 
Group Treatment N 
1 Control-no 74 
treatment 
2 SRI-63-441 
5mg/Kg 4 
3 SRI 63-441 
10mg/Kg 10 
4 SRI 63-441 
15m2/kg 20 
5 SRI 63-441 
20mg/K2 8 
* died postoperatively 
• died with pulsating grafts 
.. p value N.S. 
b P value < 0.001 (t test) 
d~- aft Survival Time Hean ~pKbK 
(minutes) 
2,3,3,4,4,5,5,6,7,8,8, 216+40.0 
10,15,15,16,17,17,17,20, 
21,28,30,30,30,31,32,34, 
35,37,38,40,45,45,49,50, 
50,58,59,62,64,65,66,74, 
78,87,90,90,92,100,113, 
120,140,180,184,211,340, 
349,375,383,395,420,450, 
480,600,600,600,607,870, 
960,1200,1266,1440,1440 
17,37,70,600 
5,28,61,70,86,205,1628, 1270+602" 
1709,3150,5760 
39,108,129,180,184,220·, 2475:+560b 
240,455,600,720,1680, 
2880,3900,4320,4320,5040, 
5760,5760,5760.7200 
40.59*.60·,120·,360·, 1343+808.0 
745,2880,6480 
qA~ib II 
EFFECl l~ CYCLOSPORINE ALONE OR IN COMBINATION WITH SRI 63-441 ON 
CARDIAC ALLOGRAFl SURVIVAL IN PRESENSITIZED RATS 
1 
11 
12 
13 
14 
Treatment 
Contr-ol-no 
treatment 
N 
74 
CSA single 10 
admi ni st,· ati on-
t. hour-s 
CSA multi~le 9 
admin i st r- ation 
CSA multiple+ 10 
SRI 63-441 
10mg!kg 
CSA multi~le+ 10 
SRI 63-441 
15mg!kg 
value ( 0.05 (t test) 
b r' value N.5_ 
Ok n 
" 
Gr-aft survival Time 
(minutes) 
2,3,3,4,4,5,5,6,7.8,8, 
10.15,15,16,17,17,17,20, 
21,28,30.30,30,31,32,34, 
35,37,38,40.45,45,49,50, 
50,58,59,62,64,65,66,74, 
78,87,90,90,92,100,113, 
120,140,180,184,211,340, 
349,375,383,395,420,450, 
480.600,600,600.607,870, 
960,1200,1266.1440,1440 
226.235.270,330,360,615. 
9R~KPSMMI4POMI4POM 
5,15,244,250,570.629. 
2880,5760.15840 
61,76,80.105,125.140, 
304,517,7200,7200 
15.40.52,101,115.120, 
630.1140,7200.8640 
216'!40.0 
1523+566a 
2190+1736 b 
1581+938b 
1805,! 1031 b 
TAPLE III 
THE EFFECT OF PROSTAGLANDIN (PGE2) ALONE OR IN COM8INATION WITH SRI 63-
441 ON CARDIAC ALLOGRAFT SURVIVAL IN PRESENSITIZED RATS 
Grou:-:, 
1 
6 
7 
Treatment 
Cont.rol-no 
treatment. 
PGE2 alone 
PGE2+SRI 63-
441 1Rm~/kg 
N 
74 
10 
10 
+ died with pulsating grafts 
~ p value N.S. (t test) 
Graft pu~vival Time 
(minutes) 
2,3,3,4,4,5,5,6,7,8,8, 
10,15,15,16,17,17,17,20, 
21,28,30,30,30,31,32,34, 
35,37,38,40,45,45,49,50, 
50,58,59,62,64,65,66,74, 
78,87,90,90,92,100,113, 
120,140,180,184,211,340, 
349,375,383,395,420,450, 
480,600,600,600,607,870, 
960,1200,1266,1440,1440 
55,64,75,83,150,200, 
227,240+, 7200,10080 
3,12.13,22,46,95,110+. 
120+, 600·. 7200 
216+40.0 
1837:+-1154 a 
!'ABLE IV 
PROGRESSION OF BISTOLOGIC FINDINGS IN SEQUENTIAL 
BIOPSIES OF CONTROL AND !'REATED KIDNEYS 
Controls !'reated 
Tiae Glomerular ATN Intertitial Gloaerular ATN Interstitial 
(ain) Tbroabosis Bemorrbage !,broabosis Be.or rba.ge 
5 26 0 0 13 0 0 
15 69 0 focal 46 0 0 
30 83 0 focal 60 0 focal 
45 94 0 severe 73 0 0 
60 91 focal severe 80 0 0 
75 88 focal mooerate 77 0 0 
90 78 focal severe 97 focal mooerate 
N 
Control 15 
SRI 63-441 6 
( 4 rrgft.;g) 
• p < D..OO2 
•• p < 0.001 
TAlLE V 
EFFICT OF SB S3-«l ON CAT-TO-RAlHT 
KIDN EY XENOTBAN SJLANTA noN 
~ a.vi\lBl Urine Outprt 
(uanutes) ~F 
JD<Ivi<lBl .,., ±. s.E. 1 boLr J boLn 
45, 60, 70, 75, 84.3 ±. 5.26 0.22 ±. 0.17 0.05 ±. 0.06 
SO, 85, 85, 85, 
90, 95, 105, 110, 
120 
100, 125, 135, 133.3 ±. 8.23* 2.33 ±. 1.10 0.96 ±- 0.35** 
135, 145, 160 
FIGURE LEGENDS 
1. Photomicrograph of the myocardium from a heterotopic 
allograft (ACI --> Lewis) previously sensitized by four 
successive donor skin grafts (control). Note acute 
vasculitis and thrombosis. Slight acute inflammation noted 
in myocardial interstitium. (H+E 550x) 
2. Photomicrograph of the myocardium from a heterotopic 
allograft (ACI --> Lewis) previously sensitized by four 
successive donor skin grafts and treated with a single 
bolus of 15 mg/kg SRI 63-441 (IV). Note the lack of 
vasculitis and thrombosis. There is evidence of repair 
indicating some damage to myocardium prior to harvest. The 
exten t of repair ranged from mild to moderate in degree. 
(H+E 550x) 
3. Photomicrograph of the myocardium from a heterotopic 
allograft (AeI --> Lewis) previously sensitized by four 
successive donor skin grafts. This animal was treated with 
multiple administrations of 1.28 mg/kg/day FK 506 (1M) and 
a single bolus of 1.5 mg/kg SRI 63-441 (IV) at four minutes 
prior to organ revascularization. Note the absence of 
vasculitis and thrombosis. Endothelial swelling is 
prominent, however, as is the mild acute cellular rejection 
evident in the remaining myocardium. 
4 • * Sur v i val 0 f r e n a 1 x e n 0 g r aft aft e r pig - t 0 -d 0 g kid n e y 
transplantation assessing the effect of single and 
combination treatment with a PAl' receptor antagonist (SRI 
63-441) and two prostanoids (PGI2 and PGEl). Results are 
expressed as total survival time (mean minutes + SE) • 
5.* 
\ . 
Function of renal xenograft ~fter pig-to-dog kidney 
transplantation from experiments described in Figure 1. 
Results are expressed as total urine output for the entire 
transplant period (mean milliliters + SE) • 
6.* Platelet counts (mean + SE) determined for the renal artery 
(RA), renal vein (RV), and peripherally (P) for six sets of 
experiments in Group II (SRI 63-441 + PGI2 versus control). 
7.* Platelet counts (mean i SE) determined for the renal artery 
(RA), renal ve in (RV), and per ipherally (P) for three sets 
of experiments in Group IV (SRI 63-441 + PGEI versus PGEl) • 
8. Control renal xenograft (cat-to-rabbit): Microscopic 
section of glomerulus at 45 minutes post revascularization. 
Note thrombi in capillary loops. (H+E 480x) 
9. SRI 63-441 (4 mg/kg bolus) renal xenograft (cat-to-rabbit): 
Microscopic section of glomerulus at 45 minutes post 
revascularization. Note thrombi in capillary lumens 
particularity over right half. (H+E 480x). 
* Reprinted with permission from Makowka et al. Annals of Surgery 
206(4):482-495, 1987. 
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